TriSalus Life Sciences appoints two new directors, expands board to 11

TriSalus Life Sciences, Inc.

William Valle (Class I, term to 2027) and Gary Gordon (Class III, term to 2026) appointed Jan 29, 2025.
Valle receives $50k cash retainer plus $7.5k each for Audit and Compensation committees; initial option grant of 35k shares (3-yr vest).
Gordon receives $50k cash retainer plus $7.5k for Science & Technology Committee; same option grant structure as Valle.
No arrangements or understandings existed for selection of Valle or Gordon; no reportable transactions under Item 404(a).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gary Gordon

Director

TLSI · TriSalus Life Sciences, Inc.

Effective: 2025-01-29
Filed: January 31, 2025, 6:59 PM ET

On January 29, 2025, the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) increased the size of the Board to 11 directors and appointed William Valle as a Class I director of the Company and Gary Gordon as Class III director of the Company, with their term of office expiring at the 2027 and 2026 annual meeting of stockholders, respectively.

Appointed

William Valle

Director

TLSI · TriSalus Life Sciences, Inc.

Effective: 2025-01-29
Filed: January 31, 2025, 6:59 PM ET

On January 29, 2025, the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) increased the size of the Board to 11 directors and appointed William Valle as a Class I director of the Company and Gary Gordon as Class III director of the Company, with their term of office expiring at the 2027 and 2026 annual meeting of stockholders, respectively.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gary Gordon was appointed as Director at TriSalus Life Sciences, Inc..

Action: appointed
Role: Director

Exact text from the filing

On January 29, 2025, the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) increased the size of the Board to 11 directors and appointed William Valle as a Class I director of the Company and Gary Gordon as Class III director of the Company, with their term of office expiring at the 2027 and 2026 annual meeting of stockholders, respectively.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

William Valle was appointed as Director at TriSalus Life Sciences, Inc..

Action: appointed
Role: Director

Exact text from the filing

On January 29, 2025, the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) increased the size of the Board to 11 directors and appointed William Valle as a Class I director of the Company and Gary Gordon as Class III director of the Company, with their term of office expiring at the 2027 and 2026 annual meeting of stockholders, respectively.

View on SEC.gov

TriSalus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001826667-25-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.